Orchestra BioMed
OBIO
42 hedge funds and large institutions have $114M invested in Orchestra BioMed in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 5 reducing their positions, and 5 closing their positions.
360% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 5
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
51% more capital invested
Capital invested by funds: $75.5M → $114M (+$38.7M)
8% more funds holding
Funds holding: 39 → 42 (+3)
6.48% more ownership
Funds ownership: 30.16% → 36.64% (+6.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.09M |
| 2 |
BlackRock
New York
|
+$3.19M |
| 3 |
PA
Perceptive Advisors
New York
|
+$2.55M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.49M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$597K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Atika Capital Management
New York
|
-$453K |
| 2 |
Millennium Management
New York
|
-$378K |
| 3 |
Swiss National Bank
Zurich,
Switzerland
|
-$193K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$154K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$93.4K |
OBIO Hedge Fund Activity: Q3 2023 in Review
42 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2023, worth a combined $114M — up 51% from $75.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OBIO positions and 5 closed out — a net gain of 3 holders — while 23 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $7.09M. The largest seller was Atika Capital Management, exiting entirely with an estimated $453K sold.
- 42 institutional investors held Orchestra BioMed (OBIO) as of Q3 2023, up from 39 in Q2 2023.
- Funds reported $114M of Orchestra BioMed stock for Q3 2023, up 51% quarter-over-quarter.
- 8 funds opened new Orchestra BioMed positions in Q3 2023 and 5 closed out, a net change of +3 holders.
- The largest Orchestra BioMed buyer in Q3 2023 was Vanguard Group, an estimated $7.09M added.
- The largest Orchestra BioMed seller in Q3 2023 was Atika Capital Management, an estimated $453K sold.
Based on aggregated 13F filings for Q3 2023.